DE50012015D1 - Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs - Google Patents

Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs

Info

Publication number
DE50012015D1
DE50012015D1 DE50012015T DE50012015T DE50012015D1 DE 50012015 D1 DE50012015 D1 DE 50012015D1 DE 50012015 T DE50012015 T DE 50012015T DE 50012015 T DE50012015 T DE 50012015T DE 50012015 D1 DE50012015 D1 DE 50012015D1
Authority
DE
Germany
Prior art keywords
origin
meschymal
prevention
treatment
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE50012015T
Other languages
German (de)
English (en)
Inventor
Joern Bullerdiek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904514A external-priority patent/DE19904514A1/de
Priority claimed from DE19943786A external-priority patent/DE19943786A1/de
Priority claimed from DE19943787A external-priority patent/DE19943787A1/de
Application filed by Individual filed Critical Individual
Priority to DE50012015T priority Critical patent/DE50012015D1/de
Application granted granted Critical
Publication of DE50012015D1 publication Critical patent/DE50012015D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE50012015T 1999-02-04 2000-02-04 Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs Expired - Lifetime DE50012015D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE50012015T DE50012015D1 (de) 1999-02-04 2000-02-04 Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19904514A DE19904514A1 (de) 1999-02-04 1999-02-04 Mittel zur Prävention und/oder Behandlung von Leiomyomen
DE19943786A DE19943786A1 (de) 1999-09-13 1999-09-13 Mittel zur Prävention und/oder Behandlung von Gewebeveränderungen mesenchymalen Ursprungs
DE19943787A DE19943787A1 (de) 1999-09-13 1999-09-13 Mittel zur Prävention und/oder Behandlung von Gewebeveränderungen mesenchymalen Ursprungs
PCT/DE2000/000364 WO2000045851A2 (de) 1999-02-04 2000-02-04 Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
DE50012015T DE50012015D1 (de) 1999-02-04 2000-02-04 Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs

Publications (1)

Publication Number Publication Date
DE50012015D1 true DE50012015D1 (de) 2006-03-30

Family

ID=27218954

Family Applications (2)

Application Number Title Priority Date Filing Date
DE50012015T Expired - Lifetime DE50012015D1 (de) 1999-02-04 2000-02-04 Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
DE10080190T Expired - Fee Related DE10080190D2 (de) 1999-02-04 2000-02-04 Mittel zur Prävention und/oder Behandlung einer Gewebeveränderung mesenchymalen Ursprungs

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE10080190T Expired - Fee Related DE10080190D2 (de) 1999-02-04 2000-02-04 Mittel zur Prävention und/oder Behandlung einer Gewebeveränderung mesenchymalen Ursprungs

Country Status (8)

Country Link
US (2) US20070202115A1 (enExample)
EP (1) EP1146881B1 (enExample)
JP (1) JP2002536345A (enExample)
AT (1) ATE314854T1 (enExample)
AU (1) AU776955B2 (enExample)
CA (1) CA2360942A1 (enExample)
DE (2) DE50012015D1 (enExample)
WO (1) WO2000045851A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011042901A2 (en) 2009-10-07 2011-04-14 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Brucella phage polynucleotides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016629A2 (en) * 1994-11-18 1996-06-06 Amira Inc Phosphinic creatine compounds having antiviral activity
US5972666A (en) * 1996-07-26 1999-10-26 G. D. Searle & Co. Assembly-deficient herpesvirus vaccine
GB9623522D0 (en) * 1996-11-11 1997-01-08 Pharmacia & Upjohn Spa Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives

Also Published As

Publication number Publication date
ATE314854T1 (de) 2006-02-15
AU776955B2 (en) 2004-09-30
CA2360942A1 (en) 2000-08-10
WO2000045851A3 (de) 2000-12-28
JP2002536345A (ja) 2002-10-29
AU3145400A (en) 2000-08-25
WO2000045851A2 (de) 2000-08-10
US20070202115A1 (en) 2007-08-30
DE10080190D2 (de) 2002-01-24
EP1146881A2 (de) 2001-10-24
EP1146881B1 (de) 2006-01-04
US20090304708A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
NZ517616A (en) Use of retigabin for treating neuropathic pain
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69938179D1 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
ATE312079T1 (de) Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DE60002226D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l-carnitin derivate und ginkgo biloba extrakte
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
MXPA00007394A (es) Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas.
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
PL373528A1 (en) Medicine for preventing and treating bromidrosis
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
DE50012015D1 (de) Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
DE60006519D1 (de) Glutathion-reduktase zur behandlung und prophylaxe von aids
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
ATE337004T1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE275949T1 (de) Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition